Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
In the citing paper
“In contrast to these negative regulators of insulin action, SIRT1 appears to be a positive regulator of insulin sensitivity (43,44).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [43]
In the citing paper
“Additionally, the non-naturally occurring sirtuin-activating compound, SRT1720, has enhanced insulin sensitivity and oxidative metabolism in animal models of obesity, in part, by improving mitochondrial oxidative capacity231.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [231]
In the citing paper
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218). These compounds also improve insulin sensitivity in obese rodents (218).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Self-citationTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Self-citationSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Self-citation
Research works printed but not linked: 1
- Banks A, et al. Overexpression of the Sirtuin SIRT1 increases insulin sensitivity in aging mice. Diabetes. 2007;56(S1):0234-OR. [Google Scholar]
Cited by
Items 601–700 of 1,004
Wine’s Phenolic Compounds and Health: A Pythagorean View
Visioli, F., Panaite, S.-A., & Tomé‐Carneiro, J. (2020) · Molecules · doi:10.3390/molecules25184105 · Cited by 76
“The molecular rationale for studying it is the finding that resveratrol and, maybe, other wine (poly)phenols activate SIRT1, a modulator of pathways downstream of calorie restriction that produces beneficial effects on glucose homeostasis and insulin sensitivity [72,73].”
BackgroundMolecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer
Paredes, S., Villanova, L., & Chua, K. F. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1547 · Cited by 69
Mediobasal Hypothalamic SIRT1 Is Essential for Resveratrol’s Effects on Insulin Action in Rats
Knight, C. M., Gutierrez-Juarez, R., Lam, T. K. T., Arrieta-Cruz, I., Huang, L., Schwartz, G., Barzilai, N., & Rossetti, L. (2011) · Diabetes · doi:10.2337/db10-0987 · Cited by 66
“Acetylation of lysine 379 in p53 (Acp53) was used as a marker of SIRT1 activity (14,36).”
BackgroundMethodSIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress
McBurney, M. W., Clark-Knowles, K. V., Caron, A. Z., & Gray, D. A. (2013) · Genes & Cancer · doi:10.1177/1947601912474893 · Cited by 72
“A recent investigation of the “acetylome” identified 485 acetylated peptides that are upregulated more than 2-fold in mouse embryo fibroblasts lacking SIRT1.”
BackgroundInfluentialDistinctive Roles of Sirtuins on Diabetes, Protective or Detrimental?
Song, J., Yang, B., Jia, X., Li, M., Tan, W. F., Ma, S., Shi, X., & Feng, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00724 · Cited by 72
“SIRT1 activators exert similar effects like CR (85, 86).”
BackgroundZhang, J. C., Zou, L., Shi, D., Liu, J., Zhang, J., Zhao, R., Wang, G., Zhang, L., Ouyang, L., & Liu, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02268 · Cited by 69
Shiota, A., Shimabukuro, M., Fukuda, D., Soeki, T., Sato, H., Uematsu, E., Hirata, Y., Kurobe, H., Maeda, N., Sakaue, H., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-139 · Cited by 66
Hayashi, R. (2012) · Oncology Reports · doi:10.3892/or.2012.1750 · Cited by 72
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 71
“SRT1720, a synthetic small molecule activator of Sirt1, improves insulin sensitivity and glucose tolerance (Milne et al. 2007).”
BackgroundTherapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation
Zhang, M., & Tang, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114474 · Cited by 74
Gong, Y., & Lee, T. (2010) · Journal of Combinatorial Chemistry · doi:10.1021/cc100049u · Cited by 63
Yu, W., Wan, Z., Qiu, X., Chen, Y., & Dai, Y. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.60 · Cited by 66
Sirtuin 1 and Aging Theory for Chronic Obstructive Pulmonary Disease
Conti, V., Corbi, G., Manzo, V., Pelaia, G., Filippelli, A., & Vatrella, A. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/897327 · Cited by 70
“SIRT1 is implicated in aging and senescence [42, 68–70], age-associated conditions [71], including diabetes [72], neurodegenerative syndromes [73], and cardiovascular diseases [74, 75].”
Guéant, J., Akoum, R. E., Ziegler, O., Coelho, D., Feigerlová, E., Daval, J., & Guéant‐Rodriguez, R. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1339-4 · Cited by 75
“Consistently, the treatment of mice fed a high-fat diet with resveratrol and other SIRT1 agonists prevents weight gain and insulin resistance [100, 122].”
BackgroundLiang, F.-X., Chen, R., Nakagawa, A., Nishizawa, M., Tsuda, S., Wang, H., & Koya, D. (2010) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2011/735297 · Cited by 70
“…6 July 2010; Accepted 23 September 2010 Copyright © 2011 Fengxia Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original…”
Systemic regulation of mammalian ageing and longevity by brain sirtuins
Satoh, A., & Imai, S.-I. (2014) · Nature Communications · doi:10.1038/ncomms5211 · Cited by 62
Sirtuins as endogenous regulators of lung fibrosis: A current perspective
Mazumder, S., Barman, M., Bandyopadhyay, U., & Bindu, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118201 · Cited by 66
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
Dewanjee, S., Vallamkondu, J., Kalra, R. S., Chakraborty, P., Gangopadhyay, M., Sahu, R., Medala, V. K., John, A. A., Reddy, P. H., Feo, V. D., et al. (2021) · Cells · doi:10.3390/cells10061340 · Cited by 72
“Interestingly, SRT1720 was found to inhibit hepatic gluconeogenesis [191].”
BackgroundNatural Polyphenols Inhibit Lysine-Specific Demethylase-1 in vitro.
Abdulla, A., Zhao, X., & Yang, F. (2013) · PubMed · Cited by 79
SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice
Seifert, E. L., Caron, A. Z., Morin, K., Coulombe, J., He, X. H., Jardine, K. E., Dewar‐Darch, D., Boekelheide, K., Harper, M., & McBurney, M. W. (2011) · The FASEB Journal · doi:10.1096/fj.11-193979 · Cited by 66
Scuto, A., Kirschbaum, M., Buettner, R., Kujawski, M., Cermak, J. M., Atadja, P., & Jove, R. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.159 · Cited by 57
Wang, Z., Li, W., Meng, X.-L., & Jia, B. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05660.x · Cited by 67
“Resveratrol has been shown to be an activator of sirtuin1.(26,27)”
BackgroundCenteno-Baez, C., Dallaire, P., & Marette, A. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00530.2010 · Cited by 66
Epigenetics of Hepatic Insulin Resistance
Maude, H., Sanchez-Cabanillas, C., & Cebola, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.681356 · Cited by 69
“A number of studies have highlighted the role of SIRT1 as a key metabolic sensor in the liver, with some proposing it as a potential pharmacological target to ameliorate IR and T2D (113, 114).”
BackgroundChen, Y., Hamidu, S., Yang, X., Yan, Y., Wang, Q., Li, L., Oduro, P. K., & Li, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880421 · Cited by 72
“So far, SRT2104 and SRT1720 are the most promising sirtuin-activating compounds (Milne et al., 2007) with beneficial effects in treating aging-related diseases.”
BackgroundZhang, H., Ma, X., Wu, L., Zhao, Y., Zhang, P.-Y., Zhang, Y., Shao, M., Liu, F., Li, F., & Qin, G.-J. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370214557218 · Cited by 60
Aging Biology and Novel Targets for Drug Discovery
Le Couteur, D. G., McLachlan, A. J., Quinn, R. J., Simpson, S. J., & de Cabo, R. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr095 · Cited by 60
“One of these, SRT1720, improved insulin resistance and reduced glucose concentrations in rodent models of diabetes mellitus (67).”
BackgroundHow much successful are the medicinal chemists in modulation of SIRT1: A critical review
Kumar, A., & Chauhan, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.063 · Cited by 67
Synthetic approaches to oligomeric natural products
Snyder, S. A., ElSohly, A. M., & Kontes, F. (2011) · Natural Product Reports · doi:10.1039/c1np00001b · Cited by 61
After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders
Huber, K., & Superti‐Furga, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.018 · Cited by 66
NAD+ metabolism as a target for metabolic health: have we found the silver bullet?
Connell, N. J., Houtkooper, R. H., & Schrauwen, P. (2019) · Diabetologia · doi:10.1007/s00125-019-4831-3 · Cited by 59
Current Trends in Sirtuin Activator and Inhibitor Development
Bursch, K. L., Goetz, C. J., & Smith, B. C. (2024) · Molecules · doi:10.3390/molecules29051185 · Cited by 63
Mulakayala, N., Kandagatla, B., Ismail, Rapolu, R. K., Rao, P., Mulakayala, C., Kumar, C. S., Javed Iqbal, M., & Oruganti, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.003 · Cited by 63
Anticancer Agents Targeted to Sirtuins
Kozako, T., Suzuki, T., Yoshimitsu, M., Arima, N., Honda, S., & Soeda, S. (2014) · Molecules · doi:10.3390/molecules191220295 · Cited by 65
“SRT1720, SRT2183, and SRT1460 were recently described as SIRT1 activators [112].”
BackgroundResveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity
Zhang, H., Zhou, Y., Wu, M.-R., Zhou, H.-S., & Xu, F. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.07.014 · Cited by 64
SIRT1 prevents atherosclerosis via liver-X-receptor and NF-κB signaling in a U937 cell model
ZENG, H.-T., Fu, Y., Yu, W., LIN, J.-M., Liang‐Zhou, Liu, L., & Wang, W. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1460 · Cited by 63
Purushotham, A., Xu, Q., & Li, X. (2012) · The FASEB Journal · doi:10.1096/fj.11-195172 · Cited by 59
SIRT1 as a therapeutic target for Alzheimer’s disease
Wong, S. Y., & Tang, B. L. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0023 · Cited by 61
Natural Products as Modulators of Sirtuins
Karaman, B., Sippl, W., & Ntie‐Kang, F. (2020) · Molecules · doi:10.3390/molecules25143287 · Cited by 66
“Later on a weak inhibitory activity of resveratrol against the cytoplasmic sirtuin, Sirt2, and the mitochondrial sirtuin, Sirt3, was shown and similar to Sirt1, resveratrol could stimulate Sirt5 activity [91-93].”
BackgroundTan, P., Wang, M., Zhong, A., Wang, Y., Du, J., Wang, J., Qi, L., Bi, Z., Zhang, P., Lin, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01999-9 · Cited by 65
“Although SRT1720 was originally revealed to enhance SIRT1 enzymatic activities [19], our study and several other studies also found that SRT1720 treatment could increase the expression level of SIRT1 [46].”
BackgroundResultInfluentialJiang, J., Gao, Y., Wang, J., Huang, Y., Yang, R., Zhang, Y., Ma, Y., Wen, Y., Luo, G., Zhang, S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.016 · Cited by 76
Zheng, J., Chen, L., Zhang, H., Hu, X., Kong, W., & Hu, D. (2011) · Metabolism · doi:10.1016/j.metabol.2011.11.005 · Cited by 67
“Another small molecule activator of SIRT1, SRT1720, significantly reduces the hyperinsulinemia and increases the insulin-stimulated glucose disposal rate in diet-induced obesity mice after 4 weeks of supplementation, partially normalizing elevated insulin levels in a manner similar to rosiglitazone treatment [18].”
BackgroundInfluentialZillikens, M. C., van Meurs, J. B. J., Sijbrands, E. J. G., Rivadeneira, F., Dehghan, A., van Leeuwen, J. P. T. M., Hofman, A., van Duijn, C. M., Witteman, J. C. M., Uitterlinden, A. G., et al. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.12.022 · Cited by 60
Alamdari, N., Smith, I. J., Aversa, Z., & Hasselgren, P.-O. J. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00858.2009 · Cited by 59
“Although the experiments do not prove that there is a link between hyperacetylation and the catabolic response in skeletal muscle during sepsis, it may be speculated that targeted inhibition of hyperacetylation, for example by stimulating HDAC activity (38), may be a method by which muscle wasting can be prevented in…”
The tumor suppressors pRB and p53 as regulators of adipocyte differentiation and function
Hallenborg, P., Feddersen, S., Madsen, L., & Kristiansen, K. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590802680141 · Cited by 58
“The search for more potent activators than resveratrol is currently ongoing and results with respect to their effect on insulin sensitivity and mitochondrial capacity are promising [96] .”
BackgroundGuan, Y., & Hao, C. (2015) · Kidney Diseases · doi:10.1159/000440967 · Cited by 61
Khader, A., Yang, W.-L., Godwin, A. K., Prince, J. M., Nicastro, J. M., Coppa, G. F., & Wang, P. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001637 · Cited by 59
“SRT1720 is a potent activator of Sirt1 (25).”
BackgroundMethodXu, Y.-C., Xu, Y., Zhao, T., Wu, L., Yang, S.-B., & Luo, Z. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.114420 · Cited by 61
Yeast as a model to study mitochondrial mechanisms in ageing
de Barros, M. H., da Cunha, F. M., de Oliveira, G. A., Tahara, E. B., & Kowaltowski, A. J. (2010) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2010.04.008 · Cited by 69
Li, X., Wu, G., Han, F., Wang, K., Bai, X., Jia, Y., Li, Z., Cai, W., Zhang, W., Su, L., et al. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.016 · Cited by 60
Sirtuin modulators: an updated patent review (2012 – 2014)
Mellini, P., Valente, S., & Mai, A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.982532 · Cited by 60
“From 2012 to 2014 Sirtris Pharmaceuticals published five patents in which > 1500 compounds were enzymatically assayed as potential SIRT1 activators [36-40] using a mass spectrometry (MS) assay based on the fluorophore-tagged 20-aminoacid peptide substrate (Ac-Glu-Glu-Lys(biotin)-Gly-GlnSer-Thr-Ser-Ser-His-Ser-Lys(Ac)-…”
MethodInhibition of the human deacylase Sirtuin 5 by the indole GW5074
Suenkel, B., Fischer, F. F., & Steegborn, C. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.136 · Cited by 61
Dietary restriction in cerebral bioenergetics and redox state
Amigo, I., & Kowaltowski, A. J. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.021 · Cited by 61
SIRT1: Role in cardiovascular biology
Ma, L., & Li, Y. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.036 · Cited by 64
“Besides resveratrol, there are a number of other naturally occurring polyphenols, such as quercetin, fisetin and butein, and a more potent synthetic SIRT1 activator— SRT1720 [134].”
BackgroundFunction of Sirtuins in Biological Tissues
Shoba, B., Lwin, Z. M., Ling, L. S., Bay, B., Yip, G. W., & Kumar, S. D. (2009) · The Anatomical Record · doi:10.1002/ar.20875 · Cited by 57
“Studies of small molecules that function as either activators or inhibitors of sirtuin suggest that they could be used for therapy of aging-related diseases such as diabetes, obesity, atherosclerosis, cancer and neurodegenerative disorders (Milne et al., 2007; Vaquero et al., 2007).”
BackgroundSalem, I. B., Boussabbeh, M., Silva, J. P. D., Guilbert, A., Bacha, H., Abid‐Essefi, S., & Lemaire, C. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.11.012 · Cited by 62
“Growing evidence suggests that the NAD+-dependent deacetylase SIRT1 can be regarded as a new therapeutic target for the prevention of several diseases such as cancer, Alzheimer's, diabetes and atherosclerosis (Milne et al., 2007; Taylor et al., 2008).”
BackgroundSirtuin modulators: where are we now? A review of patents from 2015 to 2019
Mautone, N., Zwergel, C., Mai, A., & Rotili, D. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1749264 · Cited by 59
“activators were identified through the use of a fluorophoretagged artificial substrate, that, as in the past observed with SIRTa, can in principle produce artifacts during the measurements [9,66,70,71].”
MethodPaper-Based Biochip Assays and Recent Developments: A Review
Park, M., Kang, B., & Jeong, K. (2018) · BioChip Journal · doi:10.1007/s13206-017-2101-3 · Cited by 57
Sirtuin Modulators: Past, Present, and Future Perspectives
Fiorentino, F., Mautone, N., Menna, M., D’Acunzo, F., Mai, A., & Rotili, D. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0031 · Cited by 60
Nandave, M., Acharjee, R., Bhaduri, K., Upadhyay, J., Rupanagunta, G. P., & Ansari, M. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124581 · Cited by 63
Nϵ-Thioacetyl-Lysine-Containing Tri-, Tetra-, and Pentapeptides as SIRT1 and SIRT2 Inhibitors
Kiviranta, P. H., Suuronen, T., Wallén, E. A. A., Leppänen, J., Tervonen, J., Kyrylenko, S., Salminen, A., Poso, A., & Jarho, E. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801401k · Cited by 67
Mitochondrial sirtuins and metabolic homeostasis
Pirinen, E., Lo Sasso, G., & Auwerx, J. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.05.001 · Cited by 56
Krzysiak, T. C., Thomas, L., Choi, Y., Auclair, S., Qian, Y., Luan, S., Krasnow, S. M., Thomas, L. L., Koharudin, L. M. I., Benos, P. V., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.007 · Cited by 59
Belete, T. M. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s226113 · Cited by 66
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
Guan, Y., Greenberg, E. F., Hasipek, M., Shi, C., Liu, X., Kerr, C. M., Gackowski, D., Zarakowska, E., Radivoyevitch, T., Gu, X., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01220-9 · Cited by 70
Mitochondrial Targeting of Probes and Therapeutics to the Powerhouse of the Cell
Ma, C., Xia, F., & Kelley, S. O. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00470 · Cited by 64
Antiaging Strategies and Remedies: A Landscape of Research Progress and Promise
Tenchov, R., Sasso, J. M., Wang, X., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00532 · Cited by 73
SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty
Imai, S. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832c932d · Cited by 64
Gençoğlu, H., Tuzcu, M., Hayırlı, A., & Şahin, K. (2015) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2014.1003534 · Cited by 60
“Resveratrol is a SIRT1 activator and could improve glucose homeostasis and insulin sensitivity in liver, muscle and adipose tissue (Milne et al., 2007).”
BackgroundEpigenetic drugs against cancer: an evolving landscape
Costanzo, A. D., Gaudio, N. D., Migliaccio, A., & Altucci, L. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1315-6 · Cited by 59
Role of Sirtuin 1 in metabolic regulation
Silva, J. P., & Wahlestedt, C. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.07.001 · Cited by 59
The biochemistry and cell biology of aging: metabolic regulation through mitochondrial signaling
Long, Y. C., Tan, T. M. C., Takao, I., & Tang, B. L. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00665.2013 · Cited by 55
Sheen, J., Yu, H., Tain, Y., Tsai, W.-L., Tiao, M., Lin, I.-C., Tsai, C., Lin, Y., & Huang, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-24010-0 · Cited by 62
Krüppel-like factor 14 increases insulin sensitivity through activation of PI3K/Akt signal pathway
Yang, M. H., Ren, Y., Lin, Z., Tang, C., Jia, Y., Lai, Y., Zhou, T., Wu, S., Liu, H., Yang, G., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.07.019 · Cited by 58
Li, Z., & Han, X. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0269 · Cited by 57
Fusco, S., Maulucci, G., & Pani, G. (2012) · Cell Cycle · doi:10.4161/cc.22074 · Cited by 54
Baker, N. A., English, V. L., Sunkara, M., Morris, A. J., Pearson, K. J., & Cassis, L. A. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.08.009 · Cited by 58
“Moreover, administration of RSV improves glucose tolerance and reduces insulin resistance in mice with dietinduced obesity [20–22], in genetically obese rodents [23–25] and in humans with T2D [26].”
Protein lysine acetylation in cellular function and its role in cancer manifestation
Arif, M., Senapati, P., Shandilya, J., & Kundu, T. K. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.10.002 · Cited by 61
SRT1720 Alleviates ANIT-Induced Cholestasis in a Mouse Model
Yu, L., Liu, X., Yuan, Z., Li, X., Yang, H., Yuan, Z., Sun, L., Zhang, L., & Jiang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00256 · Cited by 57
Self-citationPossible antioxidant mechanism of coenzyme Q10 in diabetes: impact on Sirt1/Nrf2 signaling pathways
Mashayekhi, F. J., Samimi, F., Baazm, M., Eftekhar, E., Rajabi, S., & Goodarzi, M. T. (2019) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.272561 · Cited by 55
“A number of previous investigations have revealed that Sirt1 is implicated in the regulation of events that are associated with better glucose tolerance, hepatic function, and insulin sensitivity, which appear to be exerted by inducing antioxidant proteins such as Nrf2 as well as lowering pro-inflammatory cytokines (3…”
BackgroundSirtuins and the circadian clock interplay in cardioprotection: focus on sirtuin 1
Soni, S. K., Basu, P., Singaravel, M., Sharma, R., Pandi-Perumal, S. R., Cardinali, D. P., & Reiter, R. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03713-6 · Cited by 64
Duan, X., Sun, W., Sun, H., & Zhang, L. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2021.116840 · Cited by 62
Wan, X., & Garg, N. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.693051 · Cited by 58
Chen, Y., Jiang, Y., Yang, Y., Huang, X., & Sun, C. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00392-4 · Cited by 55
Direct Activation of Epac by Sulfonylurea Is Isoform Selective
Herbst, K. J., Coltharp, C., Amzel, L. M., & Zhang, J. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.007 · Cited by 55
“…Type A1 activators that can distinguish between different enzyme isoforms include the compound SRT1720 that specifically activates SIRT1 isoform (Milne et al., 2007) and xanthenone that potently activates angiotensin-converting enzyme 2 (ACE2) but does not effect ACE activity (Hernandez Prada…”
BackgroundSayd, S., Thirant, C., El-Habr, E. A., Lipecka, J., Dubois, L. G., Bogeas, A., Tahiri-Jouti, N., Chneiweiss, H., & Junier, M. (2013) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9465-0 · Cited by 55
“A major target of resveratrol for its prosurvival function is sirtuin-1 (SIRT1), which bears an allosteric site recognized by resveratrol [12].”
BackgroundNew assays and approaches for discovery and design of Sirtuin modulators
Schutkowski, M., Fischer, F. F., Roessler, C., & Steegborn, C. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.875526 · Cited by 55
“Also, deacetylation of other peptides and substrate proteins was not affected by resveratrol and other activators identified using fluorophore-labeled substrates [38,78].”
BackgroundInfluentialA fluorogenic assay for screening Sirt6 modulators
Hu, J., He, B., Bhargava, S., & Lin, H. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41138a · Cited by 58
Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status
Duan, W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0055-0 · Cited by 53
“These molecules, when used in multiple rodent animal studies, including high-fat-diet-induced obese mice, ob/ob mice, and Zucker fa/fa rats, were able to normalize glucose homeostasis by improvements in insulin sensitivity [77].”
BackgroundXu, F. L., Zheng, X., Lin, B., Liang, H., Cai, M., Cao, H., Ye, J., & Weng, J. (2016) · Obesity · doi:10.1002/oby.21393 · Cited by 58
“Accumulating evidence indicates that genetic overexpression or pharmacological activation of SIRT1 can improve obesity and insulin resistance (12-15).”
BackgroundBaltacı, S. B., Moğulkoç, R., & Baltacı, A. K. (2016) · Biomedical Reports · doi:10.3892/br.2016.777 · Cited by 66
Khan, R. S., Dine, K. E., Baumann, B. H., Lorentsen, M. K., Lin, L. Y., Brown, H., Hanson, L. R., Svitak, A. L., Wessel, H., Brown, L. R., et al. (2017) · Scientific Reports · doi:10.1038/srep41768 · Cited by 54
Skeletal Muscle Nucleo-Mitochondrial Crosstalk in Obesity and Type 2 Diabetes
Devarshi, P., McNabney, S., & Henagan, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040831 · Cited by 53
“SIRT-1 activation also prevents the development of HFD-induced insulin resistance and to improve insulin sensitivity in T2D animal models through deacetylation of PGC-1α and by increasing mitochondrial function [111,112].”
BackgroundClaudio-Catalán, M. Á., Pharande, S. G., Quezada-Soto, A., Kishore, K. G., Rentería‐Gómez, Á., Padilla‐Vaca, F., & Gámez‐Montaño, R. (2018) · ACS Omega · doi:10.1021/acsomega.8b00170 · Cited by 54
He, J., Zhang, A., Song, Z., Guo, S., Chen, Y., Liu, Z., Zhang, J., Xu, X., Liu, J., & Chu, L. (2019) · Bioscience Reports · doi:10.1042/bsr20190112 · Cited by 58
“SRT1720 is a selective activator of SIRT1 [24], we pretreated rat NP cells with 5 μ M SRT1720 and then exposed to 100 μ M H 2 O 2 for a long term to induce senescence.”
RetractedRelationship of Wine Consumption with Alzheimer’s Disease
Reale, M., Costantini, E., Jagarlapoodi, S., Khan, H., Belwal, T., & Cichelli, A. (2020) · Nutrients · doi:10.3390/nu12010206 · Cited by 52
Wang, F., Yao, S., & Xia, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110601 · Cited by 55
Type 2 diabetes, mitochondrial biology and the heart
Sack, M. N. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.02.001 · Cited by 56
“Recently identified SIRT1 activators do prevent the onset of T2DM [94] and promote fatty acid oxidation and mitochondrial function [95].”
BackgroundChen, Y. X., Zhang, M., Cai, Y., Zhao, Q., & Dai, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.066 · Cited by 56
Synthesis and anticancer evaluation of 3-aryl-6-phenylimidazo[2,1-b]thiazoles
Koppireddi, S., Chilaka, D. R. K., Avula, S., Komsani, J. R., Kotamraju, S., & Yadla, R. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.030 · Cited by 52
Metadata
- Authors
- Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J., & Westphal, C. H.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Westphal, Christoph H.
- ORCID
- Venue
- Nature
- Published
- 2007-11-29
- Volume
- 450
- Issue
- 7170
- Pages
- 712-716
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2753457
- OpenAlex
- W2116350182
- Cited by
- 1,707
- References
- 27
- Citations by year
- 2026: 38 · 2025: 43 · 2024: 55 · 2023: 55 · 2022: 68 · 2021: 100 · 2020: 80 · 2019: 75 · 2018: 82 · 2017: 69 · 2016: 92 · 2015: 89 · 2014: 110 · 2013: 119 · 2012: 126
- FWCI
- 55.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (P01AG027916, R01AG028730, R01AG019719)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- SIRT1, small molecule activators, type 2 diabetes, insulin resistance, caloric restriction mimetics, resveratrol, NAD+-dependent deacetylase, allosteric site, glucose homeostasis, mitochondrial function, obesity, aging, drug screening
- MeSH terms
- Resveratrol, Acetylation, Allosteric Site, Animals, Blood Glucose, Cell Line, Diabetes Mellitus, Type 2, Dietary Fats, Disease Models, Animal, Drosophila melanogaster, Heterocyclic Compounds, 4 or More Rings, Humans, Insulin, Male, Mitochondria, Rats, Zucker, Stilbenes, Rats, Sprague-Dawley, Catalytic Domain, Caloric Restriction, Sirtuins, Mice, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.